By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on Yarger Wealth Strategies' concentrated position in Artivion (AORT), citing thin margins, lack of clarity on the investment thesis, and potential liquidity risks.
Risk: Concentration risk and potential liquidity issues in a single-name bet
Opportunity: None identified
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Acquired 634,223 shares in Artivion; estimated trade size $25.02 million based on quarterly average price
Quarter-end position value increased by $23.23 million, reflecting both share purchase and price movement
Transaction value equaled 10.07% of reportable 13F AUM
New stake: 634,223 shares valued at $23.23 million at quarter-end
Position represents 9.35% of AUM, making it the fund's largest holding
On May 13, 2026, Yarger Wealth Strategies, LLC disclosed a new position in Artivion (NYSE:AORT), acquiring 634,223 shares in a trade estimated at $25.02 million based on quarterly average pricing.
According to a Securities and Exchange Commission (SEC) filing dated May 13, 2026, Yarger Wealth Strategies, LLC initiated a new position in Artivion by purchasing 634,223 shares. The estimated value of this transaction was $25.02 million, based on the mean unadjusted closing price for the first quarter of 2026. The quarter-end value of the holding was $23.23 million, with the change reflecting both trade size and market price movement.
As of May 15, 2026, Artivion shares were priced at $22.77 down 21.4% over the prior year, underperforming the S&P 500 by 46.6 percentage points.
| Metric | Value | |---|---| | Revenue (TTM) | $458.69 million | | Net Income (TTM) | $11.68 million | | Price (as of market close 2026-05-15) | $22.77 | | One-Year Price Change | -21.4% |
Artivion, Inc. is a global medical device company specializing in advanced cardiovascular and vascular solutions. The company leverages a diverse portfolio of proprietary products and tissue technologies to address complex surgical needs in cardiac and vascular care. Its integrated approach and focus on innovation provide a competitive advantage in serving specialized surgical markets worldwide.
Yarger Wealth Strategies runs a portfolio built almost entirely on ETFs — dividend growers, buffered equity funds, bond exposure — with individual stocks appearing mostly as small satellite positions. Artivion breaks that pattern decisively. At roughly 9% of reportable assets, it's the firm's single largest holding, ahead of every ETF in the portfolio, including long-standing positions in TDVG and VONG. That's not a toe-dip; it's a deliberate, concentrated bet on one name. The stock has had a rough stretch. Artivion shares fell roughly 20% over the past year and trailed the S&P 500 by more than 46 percentage points over that same window. Yarger stepped in during that weakness, which puts the firm on the contrarian side of this trade. Artivion makes cardiac and vascular surgical products — a narrow, specialized market with a relatively stable demand base. Whether that business fundamentals story holds up at current prices is the actual question. For investors already in cardiovascular medtech, the position size here is worth noting as a signal of conviction, not necessarily a reason to follow.
Before you buy stock in Artivion, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Artivion wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 17, 2026. *
Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vanguard High Dividend Yield ETF. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The extreme concentration of a small-cap medtech stock in a previously ETF-focused portfolio indicates a high-risk gamble rather than a fundamental value opportunity."
Yarger Wealth Strategies’ pivot from a diversified ETF-heavy portfolio to a 9% concentration in Artivion (AORT) is a massive red flag, not a signal of conviction. With a TTM net income of only $11.68 million on $458 million in revenue, the company’s 2.5% net margin is razor-thin, leaving it highly vulnerable to rising COGS or supply chain friction. While the market has beaten the stock down 21.4% over the last year, this isn't necessarily a 'value' play; it’s a liquidity trap. A firm managing only $248 million in 13F assets taking such a concentrated position suggests a potential lack of institutional rigor or a desperate reach for alpha in a stagnant medical device niche.
If Yarger has proprietary insight into Artivion’s pipeline or a pending clinical catalyst for their BioGlue product, this concentration could be a high-conviction bet on a near-term valuation re-rating.
"Yarger's 9% bet on AORT is notable as a concentration signal, but without disclosed rationale, it's impossible to distinguish between contrarian value-hunting and momentum-chasing into weakness."
Yarger's 9.35% AORT concentration is presented as contrarian conviction, but the framing obscures a critical gap: we have zero insight into *why* they bought. A $25M entry into a $248M fund's largest holding demands justification—turnaround thesis? valuation floor? management change?—none of which the article provides. AORT's 2.5% net margin (TTM) on $459M revenue is thin for medtech; the -21.4% YoY decline may reflect structural headwinds, not opportunity. Yarger's ETF-heavy portfolio suggests passive indexing expertise, not deep medtech diligence. The position size screams conviction but could equally signal overconfidence in a beaten-down name.
A specialized medtech player with stable surgical demand, acquired at depressed valuation by a disciplined allocator, may simply be a rational contrarian entry—and the article's silence on *why* is just editorial laziness, not evidence of absent thesis.
"The news signals a high-conviction, single-name bet on a niche medtech that could deliver outsized gains if Artivion stabilizes and grows margins, but faces outsized downside risk from concentration, reimbursement/regulatory headwinds, and a narrow product base."
Yarger Wealth's May 2026 13F shows Artivion (AORT) as the fund's top holding at about 9.35% of its $248.4M reportable assets, a bold tilt for an ETF-heavy shop. That signals conviction but also concentration risk. On fundamentals, Artivion is a narrow cardiovascular-device play with trailing revenue around $459M and net income near $12M, and a -21% stock move over the past year. The upside would require durable demand, pricing/reimbursement stability, and margin expansion; the downside is idiosyncratic failure in a small-cap niche or a broad market rotation away from medtech. The article glosses over catalysts and liquidity/exit risks in a single-name bet.
The strongest case against this read is that a 9% AUM concentration in a single small-cap medtech stock exposes the portfolio to idiosyncratic shocks if Artivion misses milestones or reimbursement turns sour. Also, the article omits near-term catalysts or a clear growth path, making the bet overly reliant on an uncertain turnaround.
"A small advisor's outsized single-stock bet reveals more about its own risk tolerance than about sustainable upside in a low-margin medtech name."
Yarger Wealth's move to make AORT its top holding at 9.35% of $248 million AUM breaks from its ETF-centric approach and highlights a contrarian bet on a cardiovascular medtech trading down 21% over the past year. At $22.77, the stock's $458.69 million TTM revenue supports only $11.68 million in net income, pointing to thin margins that could reflect reimbursement pressure or slow adoption of products like BioGlue and stent grafts. While the $25 million purchase size signals conviction during weakness, a $248 million shop's concentrated position in a niche name rarely moves broader sentiment and may expose the fund to liquidity and single-stock volatility risks not typical of its dividend and buffered ETF core.
The underperformance could mark a genuine inflection if upcoming clinical data or procedural volume growth in cardiac surgery lifts utilization and margins faster than the market expects.
"Artivion’s razor-thin net margins make the company highly sensitive to debt service costs, which the panel has overlooked in favor of revenue growth analysis."
Claude, you’re right to focus on the 'why,' but you’re missing the regulatory angle. Artivion isn't just a medtech play; it’s a high-barrier-to-entry surgical market. If Yarger is betting on a catalyst, it’s likely the On-X or BioGlue clinical expansion. However, everyone is ignoring the debt-to-equity ratio. With such thin margins, any interest rate sensitivity in their capital structure could wipe out that $11.68M net income entirely. This isn't just a liquidity trap; it’s a potential solvency squeeze.
"Timing of entry—not just size—determines whether this is conviction or passive concentration creep."
Gemini's debt-to-equity concern is valid but unsubstantiated here—we don't have AORT's actual leverage ratios from the article. More pressing: nobody has questioned whether Yarger's $25M entry was even *recent*. The 13F is dated May 2026, but we don't know if this position was built last quarter or held for years. If it's legacy, the 9% concentration might reflect drift, not conviction. That distinction changes everything about the 'bold tilt' narrative.
"Liquidity and exit risk in a small fund make Artivion a fragile top-holding bet, regardless of any near-term catalysts."
Responding to Claude: I largely agree there’s a missing ‘why,’ but the hidden risk is liquidity and exit dynamics. A 9.3% top holding in a $248M AUM shop makes Artivion a single-name bet with outsized concentration risk; even a modest redemption or rebalancing could force forced selling, amplifying downside or capping upside regardless of any near-term catalyst. The article should quantify fund liquidity, not just margin. This structural risk deserves equal billing.
"Gemini's debt-to-equity warning is invented without data and sidesteps the critical question of position timing."
Gemini, your solvency squeeze claim on AORT's debt-to-equity lacks any balance-sheet data from the article or 13F, turning it into unsubstantiated speculation rather than a flagged risk. This distracts from the real gap Claude noted: without knowing if the 9.35% stake was built recently or drifted, we cannot separate conviction from inertia in a fund shifting away from ETFs.
The panel consensus is bearish on Yarger Wealth Strategies' concentrated position in Artivion (AORT), citing thin margins, lack of clarity on the investment thesis, and potential liquidity risks.
None identified
Concentration risk and potential liquidity issues in a single-name bet